Exact Sciences raises $25M as it advances colorectal cancer screening
This article was originally published in Scrip
Executive Summary
Exact Sciences, a US molecular diagnostics company, has announced the pricing of a public offering of 3.125 million shares of its common stock at $8 per share. The net proceeds, projected at $23.6 million, are expected to be used to gain FDA approval of its stool-based DNA colorectal cancer screening test, and other uses.